Poly(lactic acid)/poly(lactic-co-glycolic acid)-based microparticles: an overview

Abstract

Background Poly(glycolic acid), poly(lactic acid) and poly(lactic-co-glycolic acid) were approved by the United States Food and Drug Administration (FDA) in the 1970s as materials for the manufacturing of bioresorbable surgical sutures, but soon became the reference materials for the preparation of sustained release formulations, especially injectable microparticles. Since the 1986 approval of Decapeptyl ® SR, the first product based on PLGA microspheres, more than 15 such products have been approved for clinical use. Area covered This article highlights the key steps that brought to the development of injectable poly(lactic acid)/poly(lacticco-glycolic acid) microparticles for the sustained release of active pharmaceutical ingredients. After a brief history of some pioneering works that opened the field of controlled drug delivery, the key steps that led to the development of these polymers and the approval of the first microparticle-based medicinal products are reviewed. Finally, the general characteristics of these polymers are described and the classical preparation method is explained. Expert opinion Poly(lactic acid)/poly(lactic-co-glycolic acid) microparticles are among the most successful drug delivery systems. The recent approval of new medicinal products based on PLGA microspheres is the proof that pharmaceutical companies have continued to exploit this drug delivery technology. The possible development of generics and the continuous discovery of therapeutic peptides will hopefully further the success of microsphere technology.

Repositioning N-Acetylcysteine (NAC): NAC-Loaded Electrospun Drug Delivery Scaffolding for Potential Neural Tissue Engineering Application

“…This is indicative of the cytocompatility of these systems, as they did not release any toxic substances in the cell culture medium toward PC12 and A172 cell lines. This was expected, as the carefully selected polymers materials NAC and PLGA herein are FDA-approved and noted for their biocompatibility, biodegradability, and non-toxic properties [ 15 , 60 , 61 , 62 ].…”

Bio-Based Packaging: Materials, Modifications, Industrial Applications and Sustainability

“…To date, large amounts of research are ongoing about the copolymerization of lactide molecules to improve the biodegradation of PLA. For instance, glycolic acid is the most studied co-monomer used with lactic acid [ 34 , 74 , 75 ]. Block co-polymerization of PLA with poly(ethylene glycol) (PEG) is another common technique used to enhance the biodegradability of polylactide [ 34 , 75 , 76 , 77 ].…”

High‐throughput, aseptic production of injectable Tetra‐PEG hydrogel microspheres for delivery of releasable covalently bound drugs

“…Most MS drug delivery systems encapsulate drugs noncovalently within a polymer cross‐linked with ester bonds such that pore size prevents drug diffusion and release. Drug release occurs by diffusion as the ester cross‐links hydrolyze and pore sizes enlarge 1‐3 . However, such systems have limitations that may make them unsuitable for many uses.…”